:strip_icc():format(jpeg)/kly-media-production/medias/3052513/original/058958800_1581928401-20200217-Medis-Virus-Corona-1.jpg "Including the Worms Drug Class, Niclosamide Has Coronavirus Antivirus Potential")
Several studies have shown that niclosamide use decreases when given orally. However, through injection technology, drug effectiveness can be optimal.
“With injection technology, the performance of the drug can be maintained. So, COVID-19 patients can be treated with one injection for two weeks of hospitalization,” Sengho continued.
“Drug efficacy tests were carried out on civets. As a result, there is an inhibitory effect of the virus. Phase one clinical trials are underway in South Korea, India and the Philippines.”
As an emergency use for COVID-19, niclosamide will be mass produced around the third quarter of 2021. Through special trials, niclosamide’s effect is not only for the treatment of COVID-19, but also for other viruses.
“We will develop niclosamide as a therapeutic agent,” said Sengho.
– .
